Overexpression of Hedgehog signaling molecules and its involvement in triple-negative breast cancer

被引:60
|
作者
Tao, Yajun [2 ]
Mao, Jun [1 ]
Zhang, Qingqing [1 ]
Li, Lianhong [1 ]
机构
[1] Dalian Med Univ, Dept Pathol, Dalian 116044, Liaoning, Peoples R China
[2] Dalian Univ, Coll Med, Dept Pathol, Dalian 116622, Liaoning, Peoples R China
关键词
Sonic Hedgehog; Patched-1; Smoothened; glioma-associated oncogene homoglog 1; triple-negative breast cancer; cancer stem cell; BASAL-CELL CARCINOMAS; STEM-CELLS; SONIC HEDGEHOG; SELF-RENEWAL; EXPRESSION; PATHWAY; GENE; SURVIVAL; THERAPY;
D O I
10.3892/ol.2011.357
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of this study was to investigate the activation of Hedgehog (Hh) signaling molecules and its involvement in triple-negative breast cancer (TNBC). A total of 123 cases of paraffin blocks, including 83 cases of primary breast carcinoma, 30 cases of mammary hyperplasia and 10 cases of normal breast tissue, were immunohistochemically analyzed for Sonic Hedgehog (SHH), Patched-1 (PTCH1), Smoothened (SMO) and glioma-associated oncogene homoglog 1 (GLI1) expression. The expression of SMO and Gill in TNBC was significantly increased in comparison to non-triple-negative breast cancer (nTNBC). GLI1 expression manifested an inverse association with the estrogen receptor. The levels of GLI1 expression were increased in lymph node-positive cases. The expression of SHH and SMO was increased in high histological grades. Furthermore, the expression of SMO and GLI1 was correlated with superior tumor stage. The expression of SHH, SMO and GLI1 was significantly increased in breast cancer and mammary hyperplasia. PTCH1 expression was significantly decreased in breast cancer compared to mammary hyperplasia and normal breast tissue. For the first time, clinical evidence has been provided in support of significant roles of Rh signaling in TNBC. Hh signaling is involved in breast ductal changes and malignant transformation. Measures to inhibit Hh activity may improve the prognosis of TNBC patients.
引用
收藏
页码:995 / 1001
页数:7
相关论文
共 50 条
  • [41] Immunotherapy in Triple-Negative Breast Cancer
    Emens, Leisha A.
    [J]. CANCER JOURNAL, 2021, 27 (01): : 59 - 66
  • [42] Triple-negative breast cancer: an update
    Boolbol, Susan K.
    Cate, Sarah P.
    [J]. BREAST CANCER MANAGEMENT, 2014, 3 (02) : 127 - 129
  • [43] Pembrolizumab in Triple-Negative Breast Cancer
    Sun, Ryan
    Wei, Lee-Jen
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (15): : 1435 - 1435
  • [44] A Review of Triple-Negative Breast Cancer
    Ismail-Khan, Roohi
    Bui, Marilyn M.
    [J]. CANCER CONTROL, 2010, 17 (03) : 173 - 176
  • [45] Morphotypes of the triple-negative breast cancer
    Koleckova, M.
    Kolar, Z.
    Ehrmann, J.
    Korinkova, G.
    Trojanec, R.
    [J]. VIRCHOWS ARCHIV, 2017, 471 : S296 - S296
  • [46] Metastatic Triple-negative Breast Cancer
    Rakha, E. A.
    Chan, S.
    [J]. CLINICAL ONCOLOGY, 2011, 23 (09) : 587 - 600
  • [47] Imaging of triple-negative breast cancer
    Dogan, B. E.
    Turnbull, L. W.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 23 - 29
  • [48] Pathogenesis of Triple-Negative Breast Cancer
    Derakhshan, Fatemeh
    Reis-Filho, Jorge S.
    [J]. ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE, 2022, 17 : 181 - 204
  • [49] Targeting triple-negative breast cancer
    Kirkpatrick, Peter
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (01) : 21 - 21
  • [50] Pembrolizumab for triple-negative breast cancer
    Stirrups, Robert
    [J]. LANCET ONCOLOGY, 2020, 21 (04): : E183 - E183